Aberrant Heparan Sulfate Profile in the Human Diabetic Kidney Offers New Clues for Therapeutic Glycomimetics

American Journal of Kidney Diseases

Volumn 48, Issue 2, 2006, Pages 250-261

  Wijnhoven, Tessa J M ^a   Lensen, Joost F M ^a   Rops, Angelique L W M M ^a   van der Vlag, Johan ^a   Kolset, Svein O ^a   Bangstad, Hans Jacob ^a   Pfeffer, Per ^a   van den Hoven, Mabel J W ^a   Berden, Jo H M ^a   van den Heuvel, Lambert P W J ^a   van Kuppevelt, Toin H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes; fibroblast growth factor 2; glycosaminoglycans; heparan sulfate; heparin; kidney

Indexed keywords

ANTIBODY; BIOMIMETIC MATERIAL; DALTEPARIN; DANAPAROID; ENOXAPARIN; FIBROBLAST GROWTH FACTOR 2; GLYCOMIMETIC AGENT; GROWTH FACTOR; HEPARAN SULFATE; HEPARAN SULFATE ANTIBODY; HEPARIN; HEPARIN DERIVATIVE; NADROPARIN; SULFATE; SULODEXIDE; UNCLASSIFIED DRUG; VESSEL DUE F;

ADULT; ALBUMINURIA; ARTICLE; BASEMENT MEMBRANE; BINDING ASSAY; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY PROXIMAL TUBULE; MALE; MESANGIUM; MICROALBUMINURIA; MOLECULAR PROBE; PHAGE DISPLAY; STRUCTURE ANALYSIS;

ADOLESCENT; ADULT; ALBUMINURIA; ANTIBODIES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE;

EID: 33746038507     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.05.003     Document Type: Article

References (52)

1. Mauer S.M. Structural-functional correlations of diabetic nephropathy. Kidney Int 45 (1994) 612-622
2. Ibrahim H.A., and Vora J.P. Diabetic nephropathy. Baillieres Best Pract Res Clin Endocrinol Metab 13 (1999) 239-264
3. Kofoed-Enevoldsen A. Heparan sulphate in the pathogenesis of diabetic nephropathy. Diabetes Metab Rev 11 (1995) 137-160
4. Ziyadeh F.N. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int 43 (1993) 114-120
5. Brito P.L., Fioretto P., Drummond K., et al. Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int 53 (1998) 754-761
6. Danis D., Nyitrayova O., Slugen I., et al. Tubular basement membrane thickening in diabetes mellitus. Int Urol Nephrol 28 (1996) 589-592
7. Gallagher J.T. Heparan sulfate. Growth control with a restricted sequence menu. J Clin Invest 108 (2001) 357-361
8. Esko J.D., and Selleck S.B. Order out of chaos. Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71 (2002) 435-471
9. van den Born J., van Kraats A.A., Bakker M.A., et al. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 38 (1995) 161-172
10. Vernier R.L., Steffes M.W., Sisson-Ross S., and Mauer S.M. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 41 (1992) 1070-1080
11. Makino H., Ikeda S., Haramoto T., and Ota Z. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy. Nephron 61 (1992) 415-421
12. Tamsma J.T., van den Born J., Bruijn J.A., et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy. Decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37 (1994) 313-320
13. Jones S., and Phillips A.O. Regulation of renal proximal tubular epithelial cell hyaluronan generation. Implications for diabetic nephropathy. Kidney Int 59 (2001) 1739-1749
14. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32 (1989) 219-226
15. van Kuppevelt T.H., Dennissen M.A., van Venrooij W.J., Hoet R.M., and Veerkamp J.H. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273 (1998) 12960-12966
16. Jenniskens G.J., Oosterhof A., Brandwijk R., Veerkamp J.H., and van Kuppevelt T.H. Heparan sulfate heterogeneity in skeletal muscle basal lamina. Demonstration by phage display-derived antibodies. J Neurosci 20 (2000) 4099-4111
17. Dennissen M.A., Jenniskens G.J., Pieffers M., et al. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 277 (2002) 10982-10986
18. van de Westerlo E.M., Smetsers T.F., Dennissen M.A., et al. Human single chain antibodies against heparin. Selection, characterization, and effect on coagulation. Blood 99 (2002) 2427-2433
19. Bangstad H.J., Osterby R., Dahl-Jorgensen K., et al. Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36 (1993) 523-529
20. Bangstad H.J., Osterby R., Rudberg S., et al. Kidney function and glomerulopathy over 8 years in young patients with type I (insulin-dependent) diabetes mellitus and microalbuminuria. Diabetologia 45 (2002) 253-261
21. Reubsaet F.A., Veerkamp J.H., and Monnens L.A. Sulfated glycosaminoglycan content of glomerular and tubular basement membranes of individuals of different ages. Nephron 41 (1985) 344-347
22. Pieper J.S., Hafmans T., van Wachem P.B., et al. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res 62 (2002) 185-194
23. Lensen J.F., Rops A.L., Wijnhoven T.J., et al. Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies. J Am Soc Nephrol 16 (2005) 1279-1288
24. Szelachowska M., Poplawska A., Topolska J., et al. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 13 (1997) 539-545
25. Skrha J., Perusicova J., Pont'uch P., and Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract 38 (1997) 25-31
26. Dedov I., Shestakova M., Vorontzov A., and Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 12 (1997) 2295-2300
27. Gambaro G., Kinalska I., Oksa A., et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients. The Di.N.A.S. randomized trial. J Am Soc Nephrol 13 (2002) 1615-1625
28. Achour A., Kacem M., Dibej K., et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 18 (2005) 568-574
29. Tucker B.J., Rasch R., and Blantz R.C. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J Clin Invest 92 (1993) 686-694
30. Kunika K., Yamaoka T., and Itakura M. Damage of charge-dependent renal tubular reabsorption causes diabetic microproteinuria. Diabetes Res Clin Pract 36 (1997) 1-9
31. Tojo A., Onozato M.L., Ha H., et al. Reduced albumin reabsorption in the proximal tubule of early-stage diabetic rats. Histochem Cell Biol 116 (2001) 269-276
32. Osicka T.M., Houlihan C.A., Chan J.G., Jerums G., and Comper W.D. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 49 (2000) 1579-1584
33. Yaqoob M., McClelland P., Patrick A.W., et al. Tubular damage in microalbuminuric patients with primary glomerulonephritis and diabetic nephropathy. Ren Fail 17 (1995) 43-49
34. Hong C.Y., and Chia K.S. Markers of diabetic nephropathy. J Diabetes Complications 12 (1998) 43-60
35. Kordonouri O., Hartmann R., Muller C., Danne T., and Weber B. Predictive value of tubular markers for the development of microalbuminuria in adolescents with diabetes. Horm Res 50 (1998) S23-S27 (suppl 1)
36. Tamsma J.T., van der Woude F.J., and Lemkes H.H. Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant 11 (1996) 182-185
37. van der Pijl J.W., van der Woude F.J., Geelhoed-Duijvestijn P.H., et al. Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 8 (1997) 456-462
38. van der Pijl J.W., Lemkes H.H., Frolich M., et al. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Nephrol 10 (1999) 1331-1336
39. Gambaro G., Venturini A.P., Noonan D.M., et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46 (1994) 797-806
40. Samama M.M., and Gerotziafas G.T. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 109 (2003) 1-11
41. Yayon A., Klagsbrun M., Esko J.D., Leder P., and Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64 (1991) 841-848
42. Bai X., and Esko J.D. An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. J Biol Chem 271 (1996) 17711-17717
43. Cooper Jr. L.T., Hiatt W.R., Creager M.A., et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 6 (2001) 235-239
44. Kriz W., Hahnel B., Rosener S., and Elger M. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 48 (1995) 1435-1450
45. Mazue G., Newman A.J., Scampini G., et al. The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE 26184, human basic fibroblast growth factor. Toxicol Pathol 21 (1993) 490-501
46. Nakamura T., Fukui M., Ebihara I., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42 (1993) 450-456
47. Young B.A., Johnson R.J., Alpers C.E., et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47 (1995) 935-944
48. McAuliffe A.V., Fisher E.J., McLennan S.V., Yue D.K., and Turtle J.R. Urinary glycosaminoglycan excretion in NIDDM subjects. Its relationship to albuminura. Diabet Med 13 (1996) 758-763
49. De Muro P., Fresu P., Formato M., et al. Urinary glycosaminoglycan and proteoglycan excretion in normoalbuminuric patients with type 1 diabetes mellitus. J Nephrol 15 (2002) 290-296
50. Myrup B., Hansen P.M., Jensen T., et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345 (1995) 421-422
51. Morita Y., Makino H., Ota K., Akiyama K., and Ota Z. Beneficial effect of low molecular weight heparin ("fragmin") on proteinuria of proliferative glomerulonephritis. Clin Nephrol 42 (1994) 346-347
52. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698